Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review

Table 4 Summary of comparative efficacy: Lebrikizumab vs other systemic therapies at week 12/16

Comparison	IGA 0/1, ORs (95% CrIs)	EASI-75, ORs (95% CrIs)	Itch (week 12/16)	Overall interpretation
Lebrikizumab vs dupilumab	1.01 (0.64-1.54)	0.93 (0.65-1.33)	0.79 (0.48-1.24)	Comparable efficacy
Lebrikizumab vs tralokinumab	0.46 (0.31-0.68)	0.57 (0.40-0.81)	0.39 (0.23-0.63)	Lebrikizumab superior
Lebrikizumab vs baricitinib 2 mg	0.40 (0.23-0.66)	0.37 (0.23-0.59)	0.28 (0.15-0.51)	Lebrikizumab superior
Lebrikizumab vs baricitinib 4 mg	0.43 (0.23-0.80)	0.47 (0.28-0.78)	0.35 (0.18-0.68)	Lebrikizumab superior
Lebrikizumab vs abrocitinib 100 mg	0.70 (0.44-1.15)	0.88 (0.60-1.29)	0.78 (0.47-1.24)	Comparable efficacy
Lebrikizumab vs abrocitinib 200 mg	1.38 (0.88-2.23)	1.43 (0.99-2.10)	1.43 (0.86-2.28)	Comparable efficacy
Lebrikizumab vs upadacitinib 15 mg	1.52 (0.92-2.41)	1.38 (0.97-1.96)	1.19 (0.72-1.93)	Comparable efficacy
Lebrikizumab vs upadacitinib 30 mg	2.73 (1.67-4.32)	1.57 (1.10-2.25)	1.84 (1.08-2.93)	Upadacitinib superior

Odds ratios (ORs) (comparator vs lebrikizumab) and 95% credible intervals derived from Bayesian network meta-analysis; OR < 1 favors lebrikizumab and OR > 1 favors comparator. ORs: Odds ratios; CrIs: Credible intervals; IGA: Investigator global assessment; EASI: Eczema Area and Severity Index.